Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Income from Continuing Operations (2022 - 2025)

Historic Income from Continuing Operations for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to -$20.8 million.

  • Orchestra BioMed Holdings' Income from Continuing Operations fell 3501.88% to -$20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.1 million, marking a year-over-year decrease of 3371.97%. This contributed to the annual value of -$60.9 million for FY2024, which is 2788.26% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Income from Continuing Operations stood at -$20.8 million for Q3 2025, which was down 3501.88% from -$19.4 million recorded in Q2 2025.
  • Over the past 5 years, Orchestra BioMed Holdings' Income from Continuing Operations peaked at -$5.1 million during Q1 2022, and registered a low of -$20.8 million during Q3 2025.
  • Moreover, its 4-year median value for Income from Continuing Operations was -$13.4 million (2024), whereas its average is -$13.5 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 12513.65% in 2023, then tumbled by 1335.15% in 2024.
  • Orchestra BioMed Holdings' Income from Continuing Operations (Quarter) stood at -$9.8 million in 2022, then decreased by 15.72% to -$11.4 million in 2023, then plummeted by 42.05% to -$16.2 million in 2024, then decreased by 28.93% to -$20.8 million in 2025.
  • Its Income from Continuing Operations was -$20.8 million in Q3 2025, compared to -$19.4 million in Q2 2025 and -$18.8 million in Q1 2025.